How do you see CG? by Aderem, A & Hume, D A
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How do you see CG?
Citation for published version:
Aderem, A & Hume, DA 2000, 'How do you see CG?' Cell, vol 103, no. 7, pp. 993-6.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Cell
Publisher Rights Statement:
Copyright 2000 Cell Press
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Cell, Vol. 103, 993–996, December 22, 2000, Copyright ª 2000 by Cell Press
MinireviewHow Do You See CG?
tion of immune cells by foreign DNA appears to requireAlan Aderem*‡ and David A. Hume†
uptake into the cell by receptor-mediated endocytosis* Institute for Systems Biology
and endosome acidification, suggesting that the recog-Seattle, Washington
nition structure is either endosome-associated or cyto-† Institute for Molecular Bioscience
plasmic (Krieg and Wagner, 2000). Therapeutic applica-University of Queensland Q4072
tions of the response to foreign DNA have beenAustralia
expedited by the observation that short, CG-containing
oligonucleotides (CpG-ODN) retain activity, even when
stabilized with noncleavable phosphorothioate bonds
The mammalian immune response to microbial patho- (Krieg and Wagner, 2000). The remarkable specificity of
gens relies on both innate and adaptive components the response is seen in the observation that reversal of
(Hoffmann et al., 1999). The immediate, innate response the CG motif to GC in active CpG-ODN is sufficient
is mediated largely by white blood cells such as neutro- to abolish activity. Aside from the core dinucleotide,
phils and macrophages, cells that phagocytose and kill variation in flanking bases alters the dose response
the pathogens, and that concurrently coordinate addi- curve for activation, for example a 59 C residue (a CCG
tional host responses by synthesizing a wide range of core) reduces the efficacy (Sester, et al., 1999, Krieg
inflammatory mediators and cytokines (Aderem and Un- and Wagner, 2000). Such structure–function studies im-
derhill, 1999). In macrophages, the infectious agent is ply the existence of a recognition protein that can bind
killed and degraded within the maturing phagosome, to either single-stranded or double-stranded DNA and
and components of the pathogen are presented to T that it has exquisite specificity for the CG core in an
cells, resulting in the activation of the adaptive immune optimal context. The nature of that recognition molecule
response and the establishment of protective immunity has thus far eluded identification. Two recent papers
(Aderem and Underhill, 1999). A major challenge to the (Chu et al., 2000; Hemmi et al., 2000) promise a rapid
innate immune system is the discrimination of a large resolution of this issue, but the connection between their
number of potential pathogens from self. This challenge conclusions is not immediately apparent.
has been met by the evolution of a variety of receptors Toll-like Receptor 9 and Components
that recognize conserved motifs on pathogens that are of Its Signaling Pathway Are Required
not found in higher eukaryotes; these so called pattern- for the Response to CpG-DNA
recognition receptors recognize pathogen-associated The study of Akira and colleagues (Hemmi et al., 2000)
molecular patterns (Janeway and Medzhitov, 1998). builds on parallels between the recognition of foreign
Every organism, even bacteria, have mechanisms of DNA and other microbial products. The Toll-like recep-
innate host defense to protect against invasion by po- tors, first identified in Drosophila, have been implicated
tential pathogens. The major defense mechanism em- as the receptors that enable the innate immune system
ployed by bacteria relies on recognition of foreign DNA. to recognize classes of molecules that are common to
Bacteria methylate specific sequences in their own ge- pathogenic microorganisms but are absent or underrep-
nome and produce restriction enzymes that cleave un- resented in the host, the so-called pathogen associated
methylated sequences in the DNA of an invading patho- molecular patterns (Aderem and Ulevitch, 2000). In
gen such as a bacteriophage (Murray, 2000). Only quite mammals, TLR4 is required for the immune response to
recently have we come to recognize that specialized bacterial lipopolysaccharide (LPS), the major cell wall
immune cells in mammals can employ a very similar component of Gram-negative bacteria, while TLR2 is
mechanism. The CpG dinucleotide in particular se- required for the response to several components of
quence contexts (PuPuCGPyPy) is greatly reduced in Gram-positive organisms, including lipopeptides and
peptidoglycan as well as yeast particles (Aderem andfrequency in the mammalian genome, and where it oc-
Ulevitch, 2000). Different Toll-like receptors can alsocurs, the cytosine commonly is methylated. DNA con-
combine to extend their repertoire of detection; for ex-taining unmethylated CG motifs is able to activate mu-
ample TLR2 can combine with TLR6 to detect peptido-rine myeloid cells (macrophages and dendritic cells) and
glycan, whereas TLR2 appears to combine with a yetB lymphocytes, a response that stimulates immune de-
unknown TLR to detect lipopeptide (Ozinsky et al.,fenses that may be desirable in a therapeutic or immuno-
2000).prophylactic context (Sester et al., 1999; Wagner, 1999,
The mechanism by which TLRs stimulate the produc-Chu et al., 2000; Hemmi et al., 2000; Krieg and Wagner,
tion of inflammatory molecules is being clarified (Figure2000, and references therein). Among native foreign
1) (Janeway and Medzhitov, 1998; Aderem and Ulevitch,DNAs tested, bacterial DNA is the most active immuno-
2000). Ligation of a TLR promotes dimerization and re-modulator, but mammalian cells also can recognize and
sults in the recruitment of MyD88, an adaptor proteinrespond to yeast, insect, and nematode genomic DNA
containing two domains: a C-terminal TIR domain thatwhile ignoring high concentrations of their own DNA,
interacts with the TIR domain of the receptor, and aneven when it is demethylated (Sun et al., 1997). Activa-
N-terminal death domain. This death domain undergoes
homophilic interaction with the death domain of a serine/
threonine protein kinase known as IRAK; this leads to‡ To whom correspondence should be addressed (e-mail: aderem@
systemsbiology.org). the autophosphorylation of IRAK. Autophosphorylated
Cell
994
letion studies have supported this activation pathway,
there is clearly substantial additional complexity. For
example, many components of the signaling pathway
have homologs: at least three IRAK homologs have been
demonstrated, and these are known to compensate
partly for each other.
Akira and coworkers (Hemmi et al., 2000) deleted the
gene encoding another member of the TLR family, TLR9,
in mice. The mutation of the TLR9 gene produced viable
mice, but B cells, macrophages, and dendritic cells from
these animals failed to respond to activation by a stimu-
latory CpG-DNA, and the mice were resistant to toxic
shock elicited by CpG-DNA in vivo. By contrast, re-
sponses of the myeloid and lymphoid cells to TLR4 (LPS)
and TLR2 agonists (peptidoglycan) were retained. The
phenotype of the TLR9 knockout is consistent with ear-
lier evidence showing that the common Toll signaling
pathway, involving adaptor protein MyD88, downstream
effectors TRAF-6 and IRAK, and ultimately transcription
factor NF-kB, was activated by foreign DNA, and that
the MyD88 “knockout” was unresponsive to foreign DNA
(Hacker et al., 2000, Schnare et al., 2000). In addition,
consistent with evidence that uptake of CpG-DNA is
required for its immune stimulatory activity, Hemmi et
al. (2000) cite unpublished evidence that MyD88 colocal-
izes with vesicles containing CpG-DNA. A relationship
between the endocytic pathway and TLR signaling also
is suggested by the observation that TLR1, 2, and 6 are
recruited to phagosomes in macrophages (Aderem and
Ulevitch, 2000; Ozinsky et al., 2000).Figure 1. Signaling Pathways through which TLR9 and DNA-PK
DNA-Dependent Protein Kinase Is RequiredMight Activate the Transcription of Immune Response Genes
for Host Response to CpG-DNATLR9 has an intracellular domain that is homologous with that of
The paper of Raz and colleagues (Chu et al., 2000) buildsthe IL-1 receptor, and is known as TIR. TIR binds to a homologous
upon a quite different perspective of the nature of thedomain in an adaptor protein MyD88, which also contains a death
domain; this interacts with the death domain in the serine kinase response to foreign DNA. During the normal cell cycle,
IRAK. IRAK interacts with an adaptor protein known as TRAF6. mammalian cells scan their own genomes for damage.
TRAF6 links to the MAP3 kinase TAK-1, through an adaptor TAB2. The damage detection and repair pathways are linked
TAK-1 is involved in the activation of the transcription factor NF-kB
by a signaling mechanism designed to stop the cellthrough the activation of IkB kinases, and in the activation of the
cycle for sufficient time to permit the mutation to beAP-1 transcription family members Jun and Fos, by way of additional
corrected. Depending upon the nature and extent (re-MAP kinases. Both AP-1 transcription family members and NF-kB
are required for the transcription of immune response genes. TRAF6 pairability) of the damage, either antiapoptotic or pro-
is known to act through more than one pathway. For example, the apoptotic pathways can be activated. The response of
adaptor ECSIT bridges TRAF6 to the MAP 3-kinase MEKK-1. DNA- immune cells to foreign DNA has some parallels with
PK can activate NF-kB through the activation of IkB kinases. See the DNA damage response (Sester et al. 1999). In prolif-
the text for a more complete description of the signaling pathway.
erating macrophages, foreign DNA causes cell cycleIt is not clear how CpG-DNA activates either the TLR9 or the DNA-
arrest, but is antiapoptotic (Sester et al., 2000). SimilarPK pathway; it could do so directly or indirectly. Deletion of the
anti-apoptotic effects in B cells have been analyzedgenes encoding the proteins marked with asterisks results in mice
that are unable to respond to CpG-DNA. CpG-DNA may be endocy- extensively (Yi and Krieg, 1998) although in this lineage
tosed prior to activation of DNA-PK, although how it crosses the foreign DNA can also be mitogenic. The signaling path-
endosomal membrane is unknown. way following DNA damage commonly involves a key
cell cycle regulator, the transcription factor p53. One of
the major components of the DNA damage response
IRAK then forms a complex with TRAF6 and this, in turn, is DNA-dependent protein kinase (DNA-PK), which can
results in the oligomerization of TRAF6. At this point, phosphorylate p53, leading to increased transcriptional
the details of the pathway become less clear. Somehow activation of genes involved in cell cycle arrest (Dumaz
the oligomerization of TRAF6 activates TAK-1, a mem- and Meek, 1999). This enzyme, a member of the phos-
ber of the MAP 3-kinase family, and this leads to the phatidyl-inositol-3 kinase family, is activated following
activation of the family of IkB kinases. These kinases, recognition of double-stranded DNA breaks (ends) by
in turn, phosphorylate IkB, leading to its proteolytic deg- the Ku DNA binding proteins. Recent evidence indicates
radation and the translocation of NF-kB to the nucleus. that DNA-PK can also bind single-stranded DNA ends
Concomitantly, members of the activator protein-1 (Hammarsten et al. 2000), but sequence-specific DNA
(AP-1) transcription factor family, Jun and Fos, are acti- recognition had not previously been reported. Chu et al.
vated, and both AP-1 transcription factors and NF-kB (2000) show that immunostimulatory CpG-DNA trigger
DNA-PK activation (as measured by p53 kinase activity)are required for cytokine production. Although gene de-
Minireview
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receptor activation by the endogenous ligand, spaetzle,
in Drosophila (Hoffmann et al., 1999; Aderem and Ule-
vitch, 2000). To decide between these models it will
be important to determine whether TLR9 or DNA-PK
mediate specific sequence recognition of CpG-DNA.
The effects of null mutations in mice always need to
be interpreted with caution, and it remains possible that
neither of these molecules is the specific CpG-DNA re-
ceptor. There is no obvious structural basis for the rec-
ognition of DNA by the extracellular or intracellular do-
mains of TLR9, and no evidence is presented by Hemmi
Figure 2. TLR9 and DNA-PK May Be Activated Sequentially or in et al. (2000) to show that TLR9 binds DNA directly or is
Parallel by CpG-DNA functionally altered following DNA recognition. These
In a linear model of activation, DNA-PK may be either upstream or authors examine only phosphorothioate-modified oligo-
downstream of TLR9. In the parallel model, both DNA-PK and TLR9 nucleotides. There is evidence that the phosphorothio-
signals are required for NF-kB-dependent transcription of the TNFa ate backbone is recognized independently by macro-
gene. See the text for details.
phages and amplifies some DNA response pathways
while inhibiting others (Sester et al. 2000). Hence, TLR9
could be a receptor for phosphorothioates, rather morein either affinity-purified enzyme preparations or intact
consistent with the kind of ligands bound by other TLRs.cells. They establish a plausible signaling pathway, by
As noted by the authors (Chu et al., 2000), the sequenceshowing that the activated DNA-PK enzyme can also
specificity of DNA-PK is also not clearly correlated withphosphorylate IkB-kinaseb, leading to the activation of
biological activity. Sheared mammalian DNA, or double-the key transcription factor NFkB, which is, in turn, con-
stranded non-CpG oligonucleotides, would both acti-nected to transcriptional activation of the production
vate this enzyme, yet neither mimics the response toof many inflammatory cytokine genes (Figure 1). Null
bacterial DNA or CpG oligonucleotides. It is thereforemutations in either the catalytic subunit of DNA-PK or
possible that additional molecules contribute in provid-in the IkB-kinaseb gene were found to selectively impair
ing greater molecular discrimination. Furthermore, pre-the ability of the mice, or their macrophages, to respond
vious studies have shown that a mutation in the DNA-to stimulatory CpG-DNA (or bacterial DNA) with induc-
PKcs gene (the catalytic subunit of DNA-PK) in miceible cytokine gene expression. By contrast, a mutation in
with severe combined immunodeficiency (SCID) had noa related enzyme, ataxia telangectasia-mutated (ATM),
effect on response to CpG DNA (Chace et al. 1997).which also participates in recognition of some types of
Although the SCID is not a complete null mutation ofDNA damage, had no effect on the response to immuno-
DNA-PK, it clearly has a powerful phenotypic effect.stimulatory DNA.
Recent studies have confirmed that the C-terminal do-Mechanisms by which TLR9 and DNA-PK
main of DNA-PKcs, which is missing in the SCID mouse,Might Interact
is actually needed for catalytic activity (Beamish et al.,
It is intriguing that two groups simultaneously present
2000), implying that the kinase activity of DNA-PKcs
data implicating two apparently unlinked biological
may not be required for CpG induced signaling. A resolu-
pathways in CpG-DNA detection (Figure 1). A number tion of the difference in phenotype between the SCID,
of possible models could explain the data, although no and the DNA-PKcs knockout, may give an insight into
single one of these models presently is favored. First, the precise role of this gene product.
it is possible that DNA-PK and TLR9 provide parallel An additional element that needs to be reconciled
signals that are both required for innate immune activa- with the models described above is the requirement for
tion. In this model both pathways lead to NFkB activation endocytosis in the CpG-DNA response; obviously this
as described in Figure 1. The weakness of this model adds considerable complexity. Since we do not yet know
is that the TLR9 pathway is derived by analogy with the the localization of TLR9, it is possible that ligand must
TLR4 pathway, and that DNA-PK is not required for be delivered to the receptor via an acidified endocytic
activation of NFkB by TLR4 (as implied by the lack of compartment. Alternatively, endocytosis may be re-
any effect of the mutation of the enzyme on the response quired for TLR9 signaling. Finally, if DNA-PK is the recep-
of macrophages to LPS). However, since we have an tor for CpG-DNA, its localization within the nucleus and
incomplete understanding of the TLR4 pathway, it is cytoplasm would require delivery of the ligand to the
possible that DNA-PK serves a function in TLR9 signal- cytoplasm, a process that might require prior endocyto-
ing that is analogous to an, as yet, undefined component sis (Figure 1). Clearly, much remains to be learned about
in the TLR4 pathway. This suggests a second model this important pathway.
where TLR9 and DNA-PK are sequentially activated in Other questions also come to mind. The deletion of
a linear signaling pathway (Figure 2). In this model TLR9 either DNA-PK or TLR9 might have additional conse-
could mediate the recognition of CpG-DNA, and DNA- quences that may indirectly affect the CpG-DNA recog-
PK could be part of its downstream signaling pathway. nition pathway. For example, DNA-PK has a central role
Alternatively, DNA-PK could mediate CpG-DNA recogni- in the generation of immunoglobulin and T cell receptor
tion and activate a downstream signaling pathway that rearrangements, and given the known interactions be-
requires TLR9. For example, DNA-PK could stimulate tween innate and adaptive immunity, indirect regulation
the production of a secreted TLR9 ligand that functions of the CpG-DNA response might also occur. Addition-
ally, the innate response to CpG-DNA is restricted toin an autocrine manner. This would be analogous to Toll
Cell
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host immune cells, whereas DNA-PK has a much wider
distribution. Regardless of these questions, there is no
doubt that the very important contributions by the
groups of Akira and Raz represent a big boost to the
study of the actions of foreign DNA and will generate
new avenues to identify immunomodulators that mimic
the actions of foreign DNA, but are more bioavailable.
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